KRAS Mutation Analysis (K-ras)
Order Name
KRAS MUTAT
Test Number: 9100025
Revision Date 08/13/2012
Test Number: 9100025
Revision Date 08/13/2012
| Test Name | Methodology | LOINC Code |
|---|---|---|
|
KRAS Mutation Analysis (K-ras)
|
Polymerase Chain Reaction |
| SPECIMEN REQUIREMENTS | ||||
|---|---|---|---|---|
| Specimen | Specimen Volume (min) | Specimen Type | Specimen Container | Transport Environment |
| Preferred | See Below | Tissue | Paraffin Block | Room Temperature |
| Instructions | Formalin fixed paraffin embedded tissue. Tissue source and block ID containing tumor are required on the requisition form. Pathology permission is required for any alternate sample types. |
|||
| GENERAL INFORMATION | |
|---|---|
| Testing Schedule | Mon, Thr |
| Expected TAT | 11-13 Days |
| Clinical Use | Activating Ras mutations can be found in human malignancies with overall frequency of 15-20%. A high incidence of Ras gene mutations has been reported in 80-90% malignant tumors of the pancreas, 30-60% in colon rectal carcinomas, and in 18-30% of hematopoietic neoplasia of myeloid origin. Ras proteins were shown to influence proliferation, differentiation, transformation, and apoptosis by relaying mitogenic and growth signals into the cytoplasma and the nucleolus. Mutations leading to an amino acid substitution at positions 12,13 and 61 are the most common in naturally occurring neoplasms and are frequent in adenocarcinomas of the pancreas, colon, and certain types of hematological malignancies. |
| Notes | Fresh Tissue may be submitted for processing in our histology department or tissue blocks may be used from earlier hospital stays or other encounters, but the KRAS Mutation order must be ordered on the patient's current encounter specific to the ordering physician and client account. |
| CPT Code(s) | 83891, 83892x2, 83898x2, 83904x4, 83909x2, 83912 |
| Lab Section | Reference Lab |